Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes

Diabetes and Metabolism

Volumn 38, Issue 2, 2012, Pages 102-112

  Detournay, B ^a   Simon, D ^b   Guillausseau, P J ^c   Joly, D ^d   Verges, B ^e   Attali, C ^f   Clement, O ^a   Briand, Y ^g   Delaitre, O ^g  

^a CEMKA EVAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f Medecine Générale   (France)

^g BOEHRINGER INGELHEIM   (France)

Author keywords

Antidiabetic treatment; Cardiovascular risk; Chronic renal insufficiency; Diabetes type 2; Glycaemic control; Prevalence; Review

Indexed keywords

ANTIDIABETIC AGENT;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FRANCE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN METABOLISM; INSULIN TREATMENT; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MACROALBUMINURIA; MEDICATION THERAPY MANAGEMENT; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FRANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PREVALENCE; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84859729197     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2011.11.005     Document Type: Review

References (65)

1. Ricci P., Blotière P.O., Weill A., Simon D., Tuppin P., Ricordeau P., et al. Diabète traité: quelles évolutions entre 2000 et 2009 en France ?. Bull Epidemiol Hebd 2010, 42-42:425-431.
2. Bringer J., Fontaine P., Detournay B., Nachit-Ouinekh F., Brami G., Eschwege E. Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study. Diabetes Metab 2009, 35:25-31.
3. ObEpi, 2009. Enquête épidémiologique nationale sur le surpoids et l'obésité. Available at: [last accessed on 22/6/11]. http://www.roche.fr/portal/eipf/france/rochefr/institutionnel/obepi_roche_2009.
4. Kusnik-Joinville O., Weill A., Salavane B., Ricordeau P., Allemand H. Diabète traité: quelles évolutions entre 2000 et 2005 ?. Prat Org Soins 2007, 38:1-12.
5. Fagot-Campagna A., Fosse S., Roudier C., Romon I., Penfornis A., Lecomte P., et al. Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine: d'importants évolutions entre Entred 2001 et Entred 2007. Bull Epidemiol Hebd 2009, 42-42:450-455.
6. Bonaldi C., Vernay M., Roudier C., Salavane B., Castetbon K., Fagot-Campagna A. Prévalence du diabète chez les adultes âgés de 18 à 74ans résidant en France métropolitaine. étude nationale nutrition santé, 2006-2007. Diabetes Metab 2009, 35:A18.
7. Varroud-Vial M., Guerci B., Attali C., Simon D., Detournay B., Halimi S., et al. Prise en charge du diabète en France: des progrès certains. Reseaux Diabete 2007, 31:4-9.
8. Detournay B., Cros S., Charbonnel B., Grimaldi A., Liard F., Cogneau J., et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab 2000, 26:363-369.
9. Recommandations pour la pratique clinique. Diagnostic de l'insuffisance rénale chronique chez l'adulte 2002, ANAES/HAS.
10. Société française de néphrologie évaluation de la fonction rénale et de la protéinurie pour le diagnostic de la maladie rénale chronique chez l'adulte. Recommandation pour la pratique clinique. Nephrol Ther 2009, 5:302-305.
11. Stengel B., Couchoud C., Helmer C., Loos-Ayav C., Kessler M. épidémiologie de l'insuffisance rénale chronique en France. Presse Med 2007, 36:1811-1821.
12. Froissart M., Rossert J., Jacquot C., Paillard M., Houillier P. Predictive performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16:763-773.
13. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
14. Rigalleau V., Beauvieux M.C., Gonzalez C., Raffaitin C., Lasseur C., Combe C., et al. The estimation of renal function in patients with diabetes. Diabetes Metab 2011, 37:359-366.
15. Stevens L.A., Nolin T.D., Richardson M.M., Feldman H.I., Lewis J.B., Rodby R., et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009, 54:33-42.
16. National Kidney, Foundation KDOQI™ Clinical Practice Guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(Suppl. 2):S1-S180.
17. National Collaborating Centre for Chronic Conditions Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care 2008, Royal College of Physicians, London.
18. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
19. Tokmakova M.P., Skali H., Kenchaiah S., Braunwald E., Rouleau J.L., Packer M., et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004, 110:3667-3673.
20. Hillege H.L., Nitsch D., Pfeffer M.A., Swedberg K., McMurray J.J., Yusuf S., et al. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
21. Marre M., Le Jeune J.J., Le Cloirec J. Pathogénie et traitement de la glomérulopathie diabétique. Med Nucl 1995, 19:376-385.
22. Brancati F.L., Whelton P.K., Randall B.L., Neaton J.D., Stamler J., Klag M.J. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997, 278:2069-2074.
23. Sampanis C. Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure. Hippokratia 2008, 12:22-27.
24. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 2009, 76:649-655.
25. Ritz E., Rychlik I., Locatelli F., Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808.
26. Lok C.E., Oliver M.J., Rothwell D.M., Hux J.E. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant 2004, 19:3098-3103.
27. Villar E., Chang S.H., McDonald S.P. Incidences, treatments, outcomes, and gender effect on survival in end-stage renal disease patients by diabetic status in Australia and New Zealand (1991-2005). Diabetes Care 2007, 30:3070-3076.
28. Villar E., Polkinghorne K.R., Chang S.H., Chadban S.J., McDonald S.P. Effect of type 2 diabetes on mortality risk associated with end-stage kidney disease. Diabetologia 2009, 52:1536-1541.
29. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39(Suppl. 1):S1-S266.
30. Registre français de traitements de suppléance de l'insuffisance rénale chronique. REIN. Agence de la biomédecine. Rapport annuel; 2008.
31. Fagot-Campagna A., Simon D., Varroud-Vial M., Ihaddadène K., Vallier N., Scaturro S., et al. Caractéristiques des personnes diabétiques traitées et adéquation du suivi médical du diabète aux recommandations officielles. Entred 2001. Bull Epidemiol Hebd 2003, 49-50:238-239.
32. Robert J., Roudier C., Poutignat N., Fagot-Campagna A., Weill A., Rudnichi A., et al. Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001. Bull Epidemiol Hebd 2009, 42-43:455-460.
33. Gross J.L., Canani L.H., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:161-188.
34. Delles C., Jardine A.G. Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes. Diabetologia 2011, 54:4-6.
35. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R. Development and progression of nephropathy in type 2 diabetes; the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
36. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabet Med 2008, 25(Suppl. 2):25-29.
37. Valmadrid C.T., Klein R., Moss S.E., Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinura in persons with older-onset diabetes mellitus. Arch Intern Med 2000, 160:1093-1100.
38. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
39. Drury P.L., Ting R., Zannino D., Ehnholm C., Flack J., Whiting M., et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011, 54:32-43.
40. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
41. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
42. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
43. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
44. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(S2):B21-B29.
45. Levin S.R., Coburn J.W., Abraira C., Henderson W.G., Colwell J.A., Emanuele N.V., et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000, 23:1478-1485.
46. Safadi R., Dranitzki-Elhalel M., Popovtzer M., Ben-Yehuda A. Metformin-induced lactic acidosis associated with acute renal failure. Am J Nephrol 1996, 16:520-522.
47. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003, 163:2594-2602.
48. Orban J.C., Ghaddab A., Chatti O., Ichai C. Metformin-associated lactic acidosis. Ann Fr Anesth Reanim 2006, 25:1046-1052.
49. Pilmore H.L. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010, 15:412-418.
50. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;(4):CD002967.
51. Graefe-Mody U., Friedrich C., Port A., Ring A., Retlich S., Heise T., et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011, 13:939-946.
52. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
53. ANAES Recommandations pour la pratique clinique. Moyens thérapeutiques pour ralentir la progression de l'insuffisance rénale chronique chez l'adulte 2004.
54. Dronovalli S., Burney B.O., Bakris G.L. Glycemic control and cardiovascular disease in chronic kidney disease. Curr Diab Rep 2009, 9:243-248.
55. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
56. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
57. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
58. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630-2633.
59. Wion-Barbot N., Halimi S. Hypoglycémies iatrogènes et troubles du rythme cardiaque chez les diabétiques. Consensus Cardio pour le Praticien 2009, 50:36-38.
60. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
61. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
62. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53:298-304.
63. UK Prospective Diabetes Study Group UK Prospective Diabetes Study 16: overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258.
64. van Staa T., Abenhaim L., Monette J. Rates of hypoglycemia in users of sulphonylureas. J Clin Epidemiol 1997, 50:735-741.
65. Gæde P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.